1
|
Viskin S, Chorin E, Rosso R, Amin AS, Wilde AA. Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not? Circulation 2024; 150:642-650. [PMID: 39159224 DOI: 10.1161/circulationaha.124.069138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/21/2024]
Abstract
Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.
Collapse
Affiliation(s)
- Sami Viskin
- Department of Cardiology, Tel-Aviv Sourasky Medical Center and School of Medicine, Tel Aviv University, Israel (S.V., E.C., R.R.)
| | - Ehud Chorin
- Department of Cardiology, Tel-Aviv Sourasky Medical Center and School of Medicine, Tel Aviv University, Israel (S.V., E.C., R.R.)
| | - Raphael Rosso
- Department of Cardiology, Tel-Aviv Sourasky Medical Center and School of Medicine, Tel Aviv University, Israel (S.V., E.C., R.R.)
| | - Ahmad S Amin
- Amsterdam University Medical Center, The Netherlands (A.S.A., A.A.W.)
| | - Arthur A Wilde
- Amsterdam University Medical Center, The Netherlands (A.S.A., A.A.W.)
| |
Collapse
|
2
|
Wilde AAM, van der Werf C. Risk scores in congenital long QT syndrome: friend or foe? Eur Heart J 2024; 45:2657-2659. [PMID: 38982981 DOI: 10.1093/eurheartj/ehae408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/11/2024] Open
Affiliation(s)
- Arthur A M Wilde
- Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
| | - Christian van der Werf
- Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
| |
Collapse
|
3
|
García-Izquierdo E, Scrocco C, Palacios-Rubio J, Assaf A, Ripoll-Vera T, Hernandez-Betancor I, Ramos-Ruiz P, Melero-Pita A, Segura-Domínguez M, Jiménez-Sánchez D, Castro-Urda V, Toquero-Ramos J, Yap SC, Behr ER, Fernández-Lozano I. Arrhythmia detection using an implantable loop recorder after a negative electrophysiology study in Brugada syndrome: Observations from a multicenter international registry. Heart Rhythm 2024; 21:1317-1324. [PMID: 38458509 DOI: 10.1016/j.hrthm.2024.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 02/29/2024] [Accepted: 03/04/2024] [Indexed: 03/10/2024]
Abstract
BACKGROUND Risk stratification in Brugada syndrome (BrS) remains controversial. In this respect, the role of the electrophysiology study (EPS) has been a subject of debate. In some centers, it is common practice to use an implantable loop recorder (ILR) after a negative EPS to help in risk stratification. However, the diagnostic value of this approach has never been specifically addressed. OBJECTIVE The aim of this study was to describe the baseline characteristics and the main findings of a diagnostic workup strategy with an ILR after a negative EPS in BrS. METHODS We conducted a retrospective international registry including patients with BrS and negative EPS (ie, noninducible ventricular tachycardia or ventricular fibrillation) before ILR monitoring. RESULTS The study included 65 patients from 8 referral hospitals in The Netherlands, Spain, and the United Kingdom (mean age, 39 ± 16 years; 72% male). The main indication for ILR monitoring was unexplained syncope/presyncope (66.2%). During a median follow-up of 39.0 months (Q1 25.0-Q3 47.6 months), 18 patients (27.7%) experienced 21 arrhythmic events (AEs). None of the patients died during follow-up. Bradyarrhythmias were the most common finding (47.6%), followed by atrial tachyarrhythmias (38.1%). Only 3 patients presented with ventricular arrhythmias. AEs were considered incidental in 12 patients (66.7%). In 11 patients (61.1%), AEs led to specific changes in treatment. CONCLUSION The use of ILR after a negative EPS in BrS is a safe strategy that reflected the high negative predictive value of EPS for ventricular arrhythmia in this syndrome. In addition, it allowed the detection of AEs in a significant proportion of patients, with therapeutic implications in most of them.
Collapse
Affiliation(s)
- Eusebio García-Izquierdo
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
| | - Chiara Scrocco
- Cardiovascular Clinical and Genomics Research Institute, St George's, University of London, and St George's University Hospitals NHS Foundation Trust, London, United Kingdom
| | | | - Amira Assaf
- Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, The Netherlands
| | - Tomás Ripoll-Vera
- Hospital Universitario Son Llatzer, IdISBa, Palma de Mallorca, Spain
| | | | - Pablo Ramos-Ruiz
- Department of Cardiology, University Hospital Santa Lucía, Cartagena, Spain
| | | | - Melodie Segura-Domínguez
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Diego Jiménez-Sánchez
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Victor Castro-Urda
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Jorge Toquero-Ramos
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Sing-Chien Yap
- Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, The Netherlands
| | - Elijah R Behr
- Cardiovascular Clinical and Genomics Research Institute, St George's, University of London, and St George's University Hospitals NHS Foundation Trust, London, United Kingdom
| | - Ignacio Fernández-Lozano
- Arrhythmia Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| |
Collapse
|
4
|
Huttelmaier MT, Fischer TH. [Cardiac channelopathies in the context of hereditary arrhythmia syndromes]. INNERE MEDIZIN (HEIDELBERG, GERMANY) 2024; 65:787-797. [PMID: 38977442 PMCID: PMC11269359 DOI: 10.1007/s00108-024-01751-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/26/2024] [Indexed: 07/10/2024]
Abstract
Genetic arrhythmia disorders are rare diseases; however, they are a common cause of sudden cardiac death in children, adolescents, and young adults. In principle, a distinction can be made between channelopathies and cardiomyopathies in the context of genetic diseases. This paper focuses on the channelopathies long and short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). Early diagnosis of these diseases is essential, as drug therapy, behavioral measures, and if necessary, implantation of a cardioverter defibrillator can significantly improve the prognosis and quality of life of patients. This paper highlights the pathophysiological and genetic basis of these channelopathies, describes their clinical manifestations, and comments on the principles of diagnosis, risk stratification and therapy.
Collapse
MESH Headings
- Humans
- Arrhythmias, Cardiac/genetics
- Arrhythmias, Cardiac/diagnosis
- Arrhythmias, Cardiac/therapy
- Arrhythmias, Cardiac/physiopathology
- Channelopathies/genetics
- Channelopathies/diagnosis
- Channelopathies/therapy
- Brugada Syndrome/genetics
- Brugada Syndrome/diagnosis
- Brugada Syndrome/physiopathology
- Brugada Syndrome/therapy
- Tachycardia, Ventricular/genetics
- Tachycardia, Ventricular/therapy
- Tachycardia, Ventricular/diagnosis
- Tachycardia, Ventricular/physiopathology
- Adolescent
- Child
- Long QT Syndrome/genetics
- Long QT Syndrome/diagnosis
- Long QT Syndrome/therapy
- Long QT Syndrome/physiopathology
- Death, Sudden, Cardiac/prevention & control
- Death, Sudden, Cardiac/etiology
- Adult
- Defibrillators, Implantable
- Electrocardiography
Collapse
Affiliation(s)
- Moritz T Huttelmaier
- Medizinische Klinik 1, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland
| | - Thomas H Fischer
- Medizinische Klinik 1, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
| |
Collapse
|
5
|
Sabbag A, Amoroso G, Tomer O, Conte G, Beinart R, Nof E, Özkartal T, Ollitrault P, Laredo M, Tovia‐Brodie O, Gandjbakhch E, de Benedictis M, ter Bekke RMA, Milman A. Clinical differences between drug-induced type 1 Brugada pattern and syndrome. J Arrhythm 2024; 40:982-990. [PMID: 39139869 PMCID: PMC11317691 DOI: 10.1002/joa3.13053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2024] [Revised: 04/16/2024] [Accepted: 04/23/2024] [Indexed: 08/15/2024] Open
Abstract
Background Diagnosis of Brugada syndrome (BrS) may be established by exposing a Type 1 Brugada pattern using a sodium channel blocker. Data on the outcomes of different patient populations with drug-induced Type 1 Brugada pattern are limited. The present study reports on the characteristics and outcome of subjects with ajmaline induced Type 1 Brugada pattern. Methods A multicenter retrospective study including all consecutive cases of ajmaline-induced Type 1 Brugada pattern from seven centers. Results A total of 260 patients (69.9% males, mean age 43.4 ± 13.5) were included. Additional characteristics included history of syncope (n = 56, 21.5%), family history of BrS (n = 58, 22.3%) or sudden cardiac death (n = 47, 18.1%) and ventricular fibrillation (n = 3, 1.2%). Patients were divided into those meeting current diagnostic criteria for drug-induced BrS (DIBrS) and compared to the drug-induced Brugada pattern (DIBrECG). Females were significantly overrepresented in the DIBrS group (n = 50, 40% vs. n = 29, 21.5%, p = .001). A significantly higher prevalence of type 2/3 Brugada ECG at baseline was found in the DIBrECG group (n = 108, 80.8% vs. n = 75, 60% in the DIBrS, p = .026). During a median follow up of three (IQR 1.50-5.32) years, a single event of significant arrhythmia occurred in the DIBrS group. Conclusion Less than half of subjects with ajmaline-induced Brugada pattern met current criteria for BrS. These individuals had very low rate of adverse outcomes during a follow up of 3 years, irrespective of the indication for the test or eligibility for the BrS diagnosis.
Collapse
Affiliation(s)
- Avi Sabbag
- Leviev Heart InstituteThe Chaim Sheba Medical CenterTel HashomerIsrael
- Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
| | | | - Orr Tomer
- Leviev Heart InstituteThe Chaim Sheba Medical CenterTel HashomerIsrael
- Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
| | | | - Roy Beinart
- Leviev Heart InstituteThe Chaim Sheba Medical CenterTel HashomerIsrael
- Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
| | - Eyal Nof
- Leviev Heart InstituteThe Chaim Sheba Medical CenterTel HashomerIsrael
- Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
| | | | - Pierre Ollitrault
- Electrophysiology Unit, Cardiology Department, Caen University HospitalUnicaenCaenFrance
| | - Mikael Laredo
- Sorbonne Université, AP‐HP, Groupe Hospitalier Pitié‐SalpêtrièreInstitut de CardiologieParisFrance
| | - Oholi Tovia‐Brodie
- Jesselson Integrated Heart CenterShaare Zedek Medical CenterJerusalemIsrael
| | - Estelle Gandjbakhch
- Electrophysiology Unit, Cardiology Department, Caen University HospitalUnicaenCaenFrance
| | | | - Rachel M. A. ter Bekke
- Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM)Maastricht University Medical CenterMaastrichtthe Netherlands
| | - Anat Milman
- Leviev Heart InstituteThe Chaim Sheba Medical CenterTel HashomerIsrael
- Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
| |
Collapse
|
6
|
Doundoulakis I, Pannone L, Brugada P, de Asmundis C. Author's Reply to - Revisiting the prognostic role of SCN5A in Brugada syndrome. Heart Rhythm 2024:S1547-5271(24)02736-X. [PMID: 38906516 DOI: 10.1016/j.hrthm.2024.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 06/10/2024] [Accepted: 06/13/2024] [Indexed: 06/23/2024]
Affiliation(s)
- Ioannis Doundoulakis
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
| | - Luigi Pannone
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
| | - Pedro Brugada
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
| | - Carlo de Asmundis
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium.
| |
Collapse
|
7
|
Rattanawong P, Shen WK. To the Editor - Revisiting the prognostic role of SCN5A in Brugada syndrome. Heart Rhythm 2024:S1547-5271(24)02735-8. [PMID: 38901522 DOI: 10.1016/j.hrthm.2024.05.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2024] [Accepted: 05/14/2024] [Indexed: 06/22/2024]
Affiliation(s)
- Pattara Rattanawong
- Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona.
| | - Win-Kuang Shen
- Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona
| |
Collapse
|
8
|
Fatunde OA, Rattanawong P, Maleszewski JJ, Murray DR, Shen WK, Pereira NL. Brugada Syndrome in a Transplanted Heart: Implications for Organ Transplant Screening Process. CIRCULATION. GENOMIC AND PRECISION MEDICINE 2024; 17:e004533. [PMID: 38651350 DOI: 10.1161/circgen.123.004533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Affiliation(s)
- Olubadewa A Fatunde
- Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix (O.A.F., P.R., W.-K.S.)
| | - Pattara Rattanawong
- Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix (O.A.F., P.R., W.-K.S.)
- Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital and Harvard Medical School, Boston (P.R.)
| | - Joseph J Maleszewski
- Department of Laboratory Medicine and Pathology (J.L.M.), Mayo Clinic Rochester, MN
- Department of Cardiovascular Medicine (J.L.M., N.L.P.), Mayo Clinic Rochester, MN
| | - David R Murray
- Department of Medicine, University of Wisconsin, Madison (D.R.M.)
| | - Win-Kuang Shen
- Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix (O.A.F., P.R., W.-K.S.)
| | - Naveen L Pereira
- Department of Cardiovascular Medicine (J.L.M., N.L.P.), Mayo Clinic Rochester, MN
| |
Collapse
|
9
|
Scrocco C, Ben-Haim Y, Ensam B, Aldous R, Tome-Esteban M, Specterman M, Papadakis M, Sharma S, Behr ER. The role for ambulatory electrocardiogram monitoring in the diagnosis and prognostication of Brugada syndrome: a sub-study of the Rare Arrhythmia Syndrome Evaluation (RASE) Brugada study. Europace 2024; 26:euae091. [PMID: 38584469 DOI: 10.1093/europace/euae091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 03/10/2024] [Indexed: 04/09/2024] Open
Abstract
AIMS Brugada syndrome (BrS) diagnosis and risk stratification rely on the presence of a spontaneous type 1 (spT1) electrocardiogram (ECG) pattern; however, its spontaneous fluctuations may lead to misdiagnosis and risk underestimation. This study aims to assess the role for repeat high precordial lead (HPL) resting and ambulatory ECG monitoring in identifying a spT1, and evaluate its prognostic role. METHODS AND RESULTS HPL resting and ambulatory monitoring ECGs of BrS subjects were reviewed retrospectively, and the presence of a spT1 associated with ventricular dysrhythmias and sudden cardiac death (SCD). Three-hundred and fifty-eight subjects (77 with spT1 pattern at presentation, Group 1, and 281 without, Group 2) were included. In total, 1651 resting HPL resting and 621 ambulatory monitoring ECGs were available for review, or adequately described. Over a median follow-up of 72 months (interquartile range - IQR - 75), 42/77 (55%) subjects in Group 1 showed a spT1 in at least one ECG. In Group 2, 36/281 subjects (13%) had a newly detected spT1 (1.9 per 100 person-year) and 23 on an HPL ambulatory recording (8%). Seven previously asymptomatic subjects, five of whom had a spT1 (four at presentation and one at follow-up), experienced arrhythmic events; survival analysis indicated that a spT1, either at presentation or during lifetime, was associated with events. Univariate models showed that a spT1 was consistently associated with increased risk [spT1 at presentation: hazard ratio (HR) 6.3, 95% confidence interval (CI) 1.4-28, P = 0.016; spT1 at follow-up: HR 3.1, 95% CI 1.3-7.2, P = 0.008]. CONCLUSION Repeated ECG evaluation and HPL ambulatory monitoring are vital in identifying transient spT1 Brugada pattern and its associated risk.
Collapse
Affiliation(s)
- Chiara Scrocco
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Yael Ben-Haim
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Bode Ensam
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Robert Aldous
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Maite Tome-Esteban
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Mark Specterman
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Michael Papadakis
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Sanjay Sharma
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| | - Elijah R Behr
- Cardiovascular Clinical Academic Group St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London SW17 0RE, UK
| |
Collapse
|
10
|
Russo V, Caturano A, Migliore F, Guerra F, Francia P, Nesti M, Conte G, Perini AP, Mascia G, Albani S, Marchese P, Santobuono VE, Dendramis G, Rossi A, Attena E, Ghidini AO, Sciarra L, Palamà Z, Baldi E, Romeo E, D'Onofrio A, Nigro G. Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: A nationwide cohort registry study. Heart Rhythm 2024; 21:555-561. [PMID: 38242222 DOI: 10.1016/j.hrthm.2024.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 01/08/2024] [Accepted: 01/11/2024] [Indexed: 01/21/2024]
Abstract
BACKGROUND There are limited real-world data on the extended prognosis of patients with drug-induced type 1 Brugada electrocardiogram (ECG). OBJECTIVE We assessed the clinical outcomes and predictors of life-threatening arrhythmias in patients with drug-induced type 1 Brugada ECG. METHODS This multicenter retrospective study, conducted at 21 Italian and Swiss hospitals from July 1997 to May 2021, included consecutive patients with drug-induced type 1 ECG. The primary outcome, a composite of appropriate ICD therapies and sudden cardiac death, was assessed along with the clinical predictors of these events. RESULTS A total of 606 patients (mean age 49.7 ± 14.7 years; 423 [69.8%] men) were followed for a median of 60.3 months (interquartile range 23.0-122.4 months). Nineteen patients (3.1%) experienced life-threatening arrhythmias, with a median annual event rate of 0.5% over 5 years and 0.25% over 10 years. The SCN5A mutation was the only predictor of the primary outcome (hazard ratio 4.54; P = .002), whereas a trend was observed for unexplained syncope (hazard ratio 3.85; P = .05). In patients who were asymptomatic at presentation, the median annual rate of life-threatening arrhythmias is 0.24% over 5 years and increases to 1.2% if they have inducible ventricular fibrillation during programmed ventricular stimulation. CONCLUSION In patients with drug-induced type 1 Brugada ECG, the annual risk of life-threatening arrhythmias is low, with the SCN5A mutation as the only independent predictor. Unexplained syncope correlated with worse clinical outcomes. Ventricular fibrillation inducibility at programmed ventricular stimulation significantly increases the median annual rate of life-threatening arrhythmias from 0.24% to 1.2% over 5 years.
Collapse
Affiliation(s)
- Vincenzo Russo
- Division of Cardiology, Department of Medical Translational Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
| | - Alfredo Caturano
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | | | - Federico Guerra
- Azienda Ospedaliera Universitaria Ospedali Riuniti Ancona, Ancona, Italy
| | - Pietro Francia
- Azienda Ospedaliero-Universitaria Sant'Andrea, Rome, Italy
| | - Martina Nesti
- Cardiovascular and Neurological Department, Ospedale San Donato, Arezzo, Italy
| | - Giulio Conte
- Cardiocentro Ticino Foundation, Lugano, Switzerland
| | | | | | | | | | - Vincenzo Ezio Santobuono
- Cardiology Unit, Department of Interdisciplinary Medicine and Policlinico of Bari, University of Bari "Aldo Moro", Bari, Italy
| | - Gregory Dendramis
- Cardiology Unit, Clinical and Interventional Arrhythmology, ARNAS, Ospedale Civico Di Cristina Benfratelli, Palermo, Italy
| | | | | | | | | | | | | | - Emanuele Romeo
- Department of Cardiology, University of Campania "Luigi Vanvitelli", Monaldi Hospital, Naples, Italy
| | - Antonio D'Onofrio
- Monaldi Hospital, Departmental Unit of Electrophysiology, Evaluation and Treatment of Arrhythmias, Naples, Italy
| | - Gerardo Nigro
- Division of Cardiology, Department of Medical Translational Sciences University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
11
|
Wilde AAM. Top stories on Brugada syndrome. Heart Rhythm 2024; 21:126-127. [PMID: 38176767 DOI: 10.1016/j.hrthm.2023.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 09/27/2023] [Accepted: 09/27/2023] [Indexed: 01/06/2024]
Affiliation(s)
- Arthur A M Wilde
- Department of Cardiology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam, The Netherlands; European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart).
| |
Collapse
|
12
|
Wilde AAM, Saenen J. Risk Stratification in Brugada Syndrome: How Low Can We Go? Circulation 2023; 148:1556-1558. [PMID: 37956226 DOI: 10.1161/circulationaha.123.066697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Affiliation(s)
- Arthur A M Wilde
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, the Netherlands (A.A.M.W.)
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, the Netherlands (A.A.M.W.)
- European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (A.A.M.W., J.S.)
| | - Johan Saenen
- European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (A.A.M.W., J.S.)
- Department of Cardiology, Antwerp University Hospital, Edegem, Belgium (J.S.)
| |
Collapse
|
13
|
Asatryan B, Postema PG, Wilde AAM. Pushing prognostic boundaries in Brugada syndrome: Trying to predict the unpredictable. Heart Rhythm 2023; 20:1368-1369. [PMID: 37451496 DOI: 10.1016/j.hrthm.2023.07.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 07/11/2023] [Indexed: 07/18/2023]
Affiliation(s)
- Babken Asatryan
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Pieter G Postema
- Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands; European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart).
| | - Arthur A M Wilde
- Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands; European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart)
| |
Collapse
|